Nano-amorphous Oral Sirolimus Formulation with Improved Exposure and Low Inter-individual Variability

Authors

  • Orsolya Basa-Dénes Tavanta Therapeutics Hungary Zrt., Madarász V. u. 47-49., H-1138 Budapest, Hungary
  • Réka Angi Tavanta Therapeutics Hungary Zrt., Madarász V. u. 47-49., H-1138 Budapest, Hungary
  • Balázs Kárpáti Tavanta Therapeutics Hungary Zrt., Madarász V. u. 47-49., H-1138 Budapest, Hungary
  • Tamás Jordán Tavanta Therapeutics Hungary Zrt., Madarász V. u. 47-49., H-1138 Budapest, Hungary
  • Zsolt Ötvös Tavanta Therapeutics Hungary Zrt., Madarász V. u. 47-49., H-1138 Budapest, Hungary

DOI:

https://doi.org/10.33892/aph.2021.91.181-183

Keywords:

sirolimus, nano-amorphous formulation, clinical pharmacokinetics, dose escalation

Published

2021-11-15

How to Cite

(1)
Basa-Dénes, O.; Angi, R.; Kárpáti, B.; Jordán, T.; Ötvös, Z. Nano-Amorphous Oral Sirolimus Formulation With Improved Exposure and Low Inter-Individual Variability. Acta Pharm Hung 2021, 91, 181-183.

Issue

Vol. 91 No. 3-4 (2021): Abstracts of DDRS 2021 Conference, November 15-17, 2021, Budapest, Hungary

Section

Short communication

Copyright (c) 2021 Acta Pharmaceutica Hungarica

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

APH is published as a diamond open-access journal under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Creative Commons License